Cutaneous Toxicity and Baseline Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Case Series

Background and Clinical Significance: Cutaneous toxicity is a frequent adverse event of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and may impair quality of life and adherence in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR), derived from a routine blood count, is an inexpensive inflammatory marker associated with prognosis in this setting, but its relationship with TKI-induced cutaneous toxicity is largely unexplored. The primary objective of this exploratory case series was to describe the frequency, timing and clinical pattern of cutaneous toxicity during the first six months of TKI therapy. As a secondary, hypothesis-generating aim, we explored whether baseline NLR differed between patients who developed cutaneous toxicity and those who did not. Case Presentation: We retrospectively reviewed ten patients with EGFR-mutated NSCLC treated with erlotinib, afatinib or osimertinib at a single Spanish regional hospital (2023–2025). Median age was 70 years (IQR 61.75–77.50); (60%) were women, (80%) had adenocarcinoma, exon 19 deletion was the most frequent alteration (60%), and (70%) received osimertinib. Cutaneous toxicity (CTCAE v5.0) occurred in five patients at three months and seven at six months, mostly grade 1; acneiform eruption predominated early and paronychia later. Median baseline NLR was numerically lower in patients with toxicity at six months (1.69 vs 2.75; p = 0.305), with no relevant difference at three months. Conclusions: In this small, single-centre, exploratory case series, cutaneous toxicity was common during the first six months of EGFR tyrosine kinase inhibitor therapy. Although patients who developed toxicity by six months had a numerically lower baseline NLR, this difference was not statistically significant and should be interpreted only as hypothesis-generating.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-16
DOI
https://doi.org/10.20944/preprints202611.1531.v1
Primary Topic
Chemotherapy-related skin toxicity
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Cutaneous Toxicity and Baseline Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Case Series

Alejandro Garcia Navarro, Gaspar Esquerdo Galiana, J.L. Duro Torrijos, Ana Ramírez Boscá et al.
Preprints.org
Chemotherapy-related skin toxicity
preprint

Cutaneous Toxicity and Baseline Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Case Series

Alejandro Garcia Navarro, Gaspar Esquerdo Galiana, J.L. Duro Torrijos, Ana Ramírez Boscá, María Esquerdo Orts, Asunción Martínez Andrés
preprint en

Abstract

Background and Clinical Significance: Cutaneous toxicity is a frequent adverse event of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and may impair quality of life and adherence in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The neutrophil-to-lymphocyte ratio (NLR), derived from a routine blood count, is an inexpensive inflammatory marker associated with prognosis in this setting, but its relationship with TKI-induced cutaneous toxicity is largely unexplored. The primary objective of this exploratory case series was to describe the frequency, timing and clinical pattern of cutaneous toxicity during the first six months of TKI therapy. As a secondary, hypothesis-generating aim, we explored whether baseline NLR differed between patients who developed cutaneous toxicity and those who did not. Case Presentation: We retrospectively reviewed ten patients with EGFR-mutated NSCLC treated with erlotinib, afatinib or osimertinib at a single Spanish regional hospital (2023–2025). Median age was 70 years (IQR 61.75–77.50); (60%) were women, (80%) had adenocarcinoma, exon 19 deletion was the most frequent alteration (60%), and (70%) received osimertinib. Cutaneous toxicity (CTCAE v5.0) occurred in five patients at three months and seven at six months, mostly grade 1; acneiform eruption predominated early and paronychia later. Median baseline NLR was numerically lower in patients with toxicity at six months (1.69 vs 2.75; p = 0.305), with no relevant difference at three months. Conclusions: In this small, single-centre, exploratory case series, cutaneous toxicity was common during the first six months of EGFR tyrosine kinase inhibitor therapy. Although patients who developed toxicity by six months had a numerically lower baseline NLR, this difference was not statistically significant and should be interpreted only as hypothesis-generating.

Preprints.org
Good health and well-being
Chemotherapy-related skin toxicity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon